Another Setback As Delays, Costs Spiral For AnGes’ Lead Product
This article was originally published in PharmAsia News
Executive Summary
AnGes MG has changed the global development tack for its troubled lead gene-based therapy, terminating a large international Phase III study in a refocusing that it hopes will save time and money.